Time to get rid of the Investigator's Global Assessment as the primary outcome for clinical trials in atopic dermatitis?

Affiliations

Comment

M de Bruin-Weller. Br J Dermatol. 2019 Jul.

. 2019 Jul;181(1):12-13.

doi: 10.1111/bjd.18037.

¹ National Expertise Center of Atopic Dermatitis, University Medical Center Utrecht, the Netherlands.

No abstract available

Comment on

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI, Simpson EL, Ardeleanu M, Thaçi D, Barbarot S, Bagel J, Chen Z, Eckert L, Chao J, Korotzer A, Rizova E, Rossi AB, Lu Y, Graham NMH, Hultsch T, Pirozzi G, Akinlade B. Silverberg JI, et al. Br J Dermatol. 2019 Jul;181(1):80-87. doi: 10.1111/bjd.17791. Epub 2019 Apr 11. Br J Dermatol. 2019. PMID: 30791102 Free PMC article. Clinical Trial.